Teva Advances Vitiligo Antibody to Phase 2b After Results

Teva said it will advance TEV-408, a Teva-discovered anti-IL-15 antibody for adults with active or stable non-segmental vitiligo, into a Phase 2b study in the fourth quarter of 2026 after encouraging Phase 1b data. The company reported improved skin pigmentation, no safety signals to date, nearly 75% facial-vitiligo improvement among evaluable patients, 42% reaching F-VASI50 and 21% reaching F-VASI75. Teva said the quarterly subcutaneous program targets IL-15, a driver of vitiligo biology, and addresses an autoimmune skin disease that can affect quality of life, self-image and daily social interactions while treatment options remain limited.